ARCHIVES

Misconduct Finding Is ‘Rare,’ OSI official Tells NCAB

This article is from The Cancer Letter archive.

Vol. 17 No. 24 | June 14, 1991

Download PDF Visit The Full Archive

Related Articles

FTC Report Disagrees With Key Provision Of Biologics Bill Backed By Companies

June 12, 2009

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

March 28, 2014

NIH Acknowledges Role Of Pasteur Virus In AIDS Test, Gives France More Royalties

July 15, 1994

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

January 8, 1999

DCE Recompetition Of Human Tissue Procurement Approved

November 23, 1990

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011